Advanced

Implementing liquid biopsies into clinical decision making for cancer immunotherapy

Quandt, Dagmar; Zucht, Hans Dieter; Amann, Arno; Wulf-Goldenberg, Anne; Borrebaeck, Carl LU ; Cannarile, Michael; Lambrechts, Diether; Oberacher, Herbert; Garrett, James and Nayak, Tapan Kumar, et al. (2017) In Oncotarget 8(29). p.48507-48520
Abstract

During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies. Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients'... (More)

During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies. Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients' outcome, valid and stable prognostic biomarkers are still missing. This might be due to the limited capacity of the technologies employed, reproducibility of results as well as assay stability and validation of results. Therefore solid approaches to assess immune regulation and modulation as well as to follow up the nature of the tumor in liquid biopsies are urgently required to discover valuable and relevant biomarkers including sample preparation, timing of the collection and the type of liquid samples. This article summarizes our knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level, which could be used for monitoring treatment efficiency, acquired therapy resistance mechanisms and the prognostic value of the liquid biopsies.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biomarker, High throughput analysis, Immunotherapy, Liquid biopsy, Tumor
in
Oncotarget
volume
8
issue
29
pages
14 pages
publisher
Impact Journals, LLC
external identifiers
  • scopus:85021176181
  • wos:000405694000149
ISSN
1949-2553
DOI
10.18632/oncotarget.17397
language
English
LU publication?
yes
id
0cf4cddd-3300-4102-bdb0-ef459bc6c380
date added to LUP
2017-08-18 12:47:10
date last changed
2018-04-08 04:59:49
@article{0cf4cddd-3300-4102-bdb0-ef459bc6c380,
  abstract     = {<p>During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies. Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients' outcome, valid and stable prognostic biomarkers are still missing. This might be due to the limited capacity of the technologies employed, reproducibility of results as well as assay stability and validation of results. Therefore solid approaches to assess immune regulation and modulation as well as to follow up the nature of the tumor in liquid biopsies are urgently required to discover valuable and relevant biomarkers including sample preparation, timing of the collection and the type of liquid samples. This article summarizes our knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level, which could be used for monitoring treatment efficiency, acquired therapy resistance mechanisms and the prognostic value of the liquid biopsies.</p>},
  author       = {Quandt, Dagmar and Zucht, Hans Dieter and Amann, Arno and Wulf-Goldenberg, Anne and Borrebaeck, Carl and Cannarile, Michael and Lambrechts, Diether and Oberacher, Herbert and Garrett, James and Nayak, Tapan Kumar and Kazinski, Michael and Massie, Charles and Schwarzenbach, Heidi and Maio, Michele and Prins, Robert and Wendik, Björn and Hockett, Richard and Enderle, Daniel and Noerholm, Mikkel and Hendriks, Hans and Zwierzina, Heinz and Seliger, Barbara},
  issn         = {1949-2553},
  keyword      = {Biomarker,High throughput analysis,Immunotherapy,Liquid biopsy,Tumor},
  language     = {eng},
  number       = {29},
  pages        = {48507--48520},
  publisher    = {Impact Journals, LLC},
  series       = {Oncotarget},
  title        = {Implementing liquid biopsies into clinical decision making for cancer immunotherapy},
  url          = {http://dx.doi.org/10.18632/oncotarget.17397},
  volume       = {8},
  year         = {2017},
}